Exparel 266 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DR26FFBL7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,498
Award facts
- Contract value 100% obligated
- $20,498.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $20,498.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 mL vials. The award, issued on November 17, 2025, represents a firm fixed-price delivery order with an ultimate completion date of December 9, 2025, and carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.999 billion ceiling value and extends through December 31, 2036.
DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier within the Department of Defense's global medical supply chain, authorized to deliver a comprehensive range of branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables to military healthcare facilities worldwide. EXPAREL is a specialty surgical anesthetic product that represents the company's capability to supply specialized pharmaceutical agents alongside routine medications and emergency therapeutics. The PPV-G GEN V program itself is part of a broader $30.3 billion Defense Logistics Agency acquisition strategy designed to modernize pharmaceutical procurement across the military health system, and DMS Pharmaceutical Group's consistent performance on numerous delivery orders since October 2025 demonstrates its operational readiness to fulfill this critical supplier role.
Quick answers
Who was awarded contract SPE2DR26FFBL7?
SPE2DR26FFBL7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 17, 2025.
How much is contract SPE2DR26FFBL7 worth?
The government has obligated $20,498 on SPE2DR26FFBL7.
Is contract SPE2DR26FFBL7 an order under another contract?
Yes. SPE2DR26FFBL7 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBL7 competed?
The extent of competition for SPE2DR26FFBL7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award